CL COLGATE PALMOLIVE CO
Perfumes, Cosmetics & Other Toilet Preparations · NYSE · SEC CIK 21665 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY5.9%
TTM net income YoY-29.4%
TTM EPS YoY-28.0%
Revenue 3-yr CAGR3.6%
Net income 3-yr CAGR9.0%
Margins
Gross margin60.6%
Operating margin14.8%
Net margin9.6%
FCF margin17.8%
EBITDA margin17.9%
Returns
ROE358.9%
ROA12.0%
ROIC (approx.)36.1%
Asset turnover1.24x
Leverage & solvency
Liabilities / assets96.2%
Debt / equity24.94x
Current ratio0.96x
Interest coverage12.64x
Cash quality & payout
Operating cash flow / net income2.13x
Accruals ratio-13.5%
Payout ratio—
Capex / revenue2.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $20.38B | $20.10B |
| Cost of revenue | $8.13B | $7.94B |
| Gross profit | $12.25B | $12.16B |
| R&D expense | $366.00M | $355.00M |
| SG&A expense | $7.90B | $7.73B |
| Operating income | $3.31B | $4.27B |
| Interest expense | $267.00M | $292.00M |
| Pretax income | $3.06B | $3.96B |
| Income tax | $798.00M | $907.00M |
| Net income | $2.13B | $2.89B |
| EBITDA | $3.94B | $4.87B |
| EPS (basic) | 2.64 | 3.53 |
| EPS (diluted) | 2.63 | 3.51 |
| Dividends declared per share | 2.08 | 2.48 |
| Weighted avg. shares (diluted) | 811.10M | 823.20M |
| Balance sheet | ||
| Cash & equivalents | $1.29B | $1.10B |
| Short-term investments | $107.00M | $160.00M |
| Receivables | $1.68B | $1.52B |
| Inventory | $2.03B | $1.99B |
| Current assets | $5.71B | $5.32B |
| PP&E, net | $4.66B | $4.42B |
| Goodwill | $3.12B | $3.27B |
| Intangibles | $1.54B | $1.76B |
| Total assets | $16.33B | $16.05B |
| Current liabilities | $6.85B | $5.76B |
| Short-term debt | $1.11B | $652.00M |
| Long-term debt | $6.87B | $7.29B |
| Total debt | $7.99B | $7.94B |
| Total liabilities | $15.96B | $15.50B |
| Shareholders' equity | $54.00M | $212.00M |
| Net debt | $6.70B | $6.84B |
| Shares outstanding | 801.24M | 812.57M |
| Cash flow statement | ||
| Operating cash flow | $4.20B | $4.11B |
| Capital expenditure | $564.00M | $561.00M |
| Free cash flow | $3.63B | $3.55B |
| Investing cash flow | -$817.00M | -$534.00M |
| Financing cash flow | -$3.26B | -$3.39B |
| Depreciation & amortization | $630.00M | $605.00M |
| Stock-based compensation | $155.00M | $135.00M |
| Share buybacks | $1.21B | $1.74B |
Free plan shows the latest 2 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.